This is presenting attack of every one drugs and drug ingredient at a Michigan-based company by Drug Administration and U.S. Food that can be lead to a scarcity of a challenging type of pain reliever.

“This action follows the company’s continued failure to meet the FDA’s current Good Manufacturing Practice requirements, which assure the quality of manufactured drugs,” Deborah M. Autor.

“The seizure may cause a shortage of one pain drug, choline magnesium trisalicylate, in particular. However, the drug is used by only a small percentage of patients and patients can find alternatives by consulting their doctor” Autor said.

“Caraco exhibited poor control of their raw materials used to make their products,” David Jaworski.

“Also we saw that the firm’s tablet manufacturing processes had higher than normal variability, which we believe has not adequately been addressed. We have also observed poor decisions being made by the company’s management who are responsible for the quality of the drug products being manufactured,” he said.

“Our goal is to get Caraco up and running safely,” Autor said. “Seizures often lead to major changes by companies that help them break a cycle of poor performance,” she noted.